Conatus Pharmaceuticals Inc. (CNAT)
(Delayed Data from NSDQ)
$0.90 USD
+0.05 (5.88%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.90 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Histogen Inc. [CNAT]
Reports for Purchase
Showing records 81 - 100 ( 226 total )
Company: Histogen Inc.
Industry: Medical - Products
No Hasty Judgement on Top-line POLT-HCV-SVR Results
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
4Q17 Recap: Multiple Key Catalysts on Track for 2018/2019; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Histogen Inc.
Industry: Medical - Products
4Q Recap: Don''t Ignore POLT! First of Four Phase 2b Readouts in 2Q18; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
Healthcare - NASH Weekly Newsletter: Kick off EASL with NASH BASH Investor Conference
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
NASH Weekly Newsletter: Launch of Our Monthly Clinicaltrials.gov Tracker
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Histogen Inc.
Industry: Medical - Products
Company: Histogen Inc.
Industry: Medical - Products
Takeaways from HCV-SVR Expert Call with Dr. Pockros
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Histogen Inc.
Industry: Medical - Products
Learn From A to Z About Cirrhosis in POLT HCV-SVR from HCV Guru - Feb. 20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Histogen Inc.
Industry: Medical - Products
Learn From A to Z About Cirrhosis in POLT HCV-SVR from HCV Guru - Feb. 20
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Histogen Inc.
Industry: Medical - Products
If Big Pharma Spent $10B+ on CAR-Ts, How Much for NASH? - Part 1
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Histogen Inc.
Industry: Medical - Products
High Ambitions, High Reward; Initiating with Buy Rating
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Histogen Inc.
Industry: Medical - Products
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.